Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

SmithKline Beecham burdened with $15 bil. albatross after Glaxo talks end.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

SMITHKLINE FACING $15 BIL. DILEMMA FOLLOWING TERMINATION OF GLAXO Wellcome merger negotiations because of the company's success in stoking investor enthusiasm for another round of mergers. The January announcements that SmithKline Beecham was in merger discussions first with American Home Products and then with Glaxo helped fuel a $15 bil. jump in SB market valuation. Following the termination of both negotiations, SB management may face pressure from shareholders if it cannot recover that same valuation level.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

Australia Calls For Companion Testing Plans For Drugs Requiring A CDx

See All
UsernamePublicRestriction

Register

PS088165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By